BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 29328367)

  • 21. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
    Ikram F; Ackermann S; Kahlert Y; Volland R; Roels F; Engesser A; Hertwig F; Kocak H; Hero B; Dreidax D; Henrich KO; Berthold F; Nürnberg P; Westermann F; Fischer M
    Mol Oncol; 2016 Feb; 10(2):344-59. PubMed ID: 26598443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN and HIF-1 directly regulate
    Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
    Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
    Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
    Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
    Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
    Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
    Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
    Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
    [No Abstract]   [Full Text] [Related]  

  • 31. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
    Nagy Z; Seneviratne JA; Kanikevich M; Chang W; Mayoh C; Venkat P; Du Y; Jiang C; Salib A; Koach J; Carter DR; Mittra R; Liu T; Parker MW; Cheung BB; Marshall GM
    Nat Commun; 2021 Mar; 12(1):1881. PubMed ID: 33767157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
    Liu Y; Liu D; Wan W
    Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
    Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
    J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL.
    Lee MW; Kim DS; Kim HR; Park HJ; Lee JW; Sung KW; Koo HH; Yoo KH
    Cell Prolif; 2019 May; 52(3):e12577. PubMed ID: 30724400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
    Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
    Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
    He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
    Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
    [No Abstract]   [Full Text] [Related]  

  • 40. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.
    Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T
    Nat Commun; 2019 Nov; 10(1):5026. PubMed ID: 31690716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.